EUROPEAN MEDICAL CANNABIS INDUSTRY SURVEY 2026-2027EUROPEAN MEDICAL CANNABIS INDUSTRY SURVEY 2026-20271. What is your company’s primary activity? Cultivation Extraction Finished Product Manufacturing Distribution Laboratory / Testing Engineering / Consulting Other2. What is your organization’s current GMP (Good Manufacturing Practice) status? Not started Early implementation Partially implemented Nearly certification-ready EU-GMP certified3. Which operational areas represent your biggest current challenges? (Select up to 3) Contamination control Documentation HVAC (Heating, Ventilation and Air Conditioning) Qualified personnel Validation / Qualification Regulatory requirements Costs / Budget Scaling operations Training Quality systems4. Which systems are currently implemented in your organization? (Multiple answers allowed) SOPs (Standard Operating Procedures) CAPA (Corrective and Preventive Actions) Environmental Monitoring Change Control Risk Management Internal Audits None of the above5. How would you rate your facility and infrastructure readiness? Very poor Poor Moderate Good Excellent6. Which statement best describes your cleanroom and controlled environment status? No controlled environments Basic environmental controls only Partial GMP cleanroom implementation Fully qualified GMP cleanrooms Advanced pharmaceutical-grade facilities7. What is the greatest risk currently affecting your operations? Human error Contamination Equipment failure Regulatory non-compliance Supply chain instability Financial pressure Lack of expertise8. How frequently does your organization perform GMP-related training? Monthly Quarterly Annually Occasionally No formal GMP training9. How prepared is your organization for a regulatory inspection today? Not prepared Minimally prepared Moderately prepared Well prepared Fully inspection-ready10. What level of investment is currently being made in compliance and operational quality? Very low Low Moderate High Very high11. What do you believe is the biggest barrier to industry growth in Europe? Regulation Costs Lack of expertise Market instability Limited investment Operational complexity Quality and compliance standards12. How do you expect the European medical cannabis industry to evolve over the next 5 years? Rapid growth Moderate growth Stable market Market decline Uncertain13. Which area requires the greatest external support? (Select up to 2) GMP compliance Validation & CQV (Commissioning, Qualification and Validation) Quality Assurance HVAC & cleanrooms Regulatory Affairs Training Contamination control Process optimization14. Would your organization benefit from an industry benchmark report comparing operational maturity across Europe? ☐ Yes ☐ No ☐ Maybe15. Would you like to receive the final survey report? Yes NoSubmit Form
